Successful Normal Vaginal Delivery in the Setting of Factor VII Deficiency Diagnosed During Pregnancy: A Case Report and Review of the Literature

Samer Barahmeh^{1, 2,} , Oadi N. Shrateh³, Afnan W.M. Jobran³, Akram Karmeh⁴, Maysam Hamarsheh² and Salsabeel Rajab²

¹Assistant Professor, Faculty of Medicine, Al-Quds University, Jerusalem, Palestine

²Department of Obstetrics and Gynecology, Al-Istishari Arab Hospital, Ramallah, Palestine

³Faculty of medicine, Al-Quds University, Jerusalem, Palestine

⁴Department of Hematology, Al-Istishari Arab Hospital, Ramallah, Palestine

Cite this paper:
Samer Barahmeh, Oadi N. Shrateh, Afnan W.M. Jobran, Akram Karmeh, Maysam Hamarsheh and Salsabeel Rajab. Successful Normal Vaginal Delivery in the Setting of Factor VII Deficiency Diagnosed During Pregnancy: A Case Report and Review of the Literature. American Journal of Medical Case Reports. 2023; 11(4):81-83. doi: 10.12691/ajmcr-11-4-5

Abstract

Introduction: An uncommon autosomal recessive genetic condition called congenital factor VII deficiency (FVIID) exists. This deficit has a wide range of clinical signs and symptoms. Pregnant women with congenital FVIID face a high risk of bleeding during and after delivery. The most popular kind of replacement therapy for FVIID is recombinant factor VIIa. For pregnant women with congenital FVIID, no standardized diagnosis or treatment strategy has been developed. Case presentation: We discuss the clinical background of a woman who was believed to have congenital FVIID when she was pregnant. The pregnant woman received recombinant factor VIIa as a preventative treatment when her cervical opening was complete. She delivered a live baby successfully without any difficulties or complications, including postpartum hemorrhage, neonatal defects, etc. Discussion and Conclusion: Pregnant women with hereditary FVIID who are at high risk of bleeding can effectively lower the incidence of postpartum hemorrhage by receiving recombinant factor VIIa as part of their prenatal care.

Keywords:
congenital factor VII deficiency diagnosis and treatment plan pregnancy perinatal management case report

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	He J, Zhou W, Lv H, Tao L, Chen X, Wang L. Novel IVS7+ 1G> T mutation of life-threatening congenital factor VII deficiency in neonates: a retrospective study in China. Medicine. 2019 Oct; 98(40).
[2]	Lee YJ, Ju DH, Yi SW, Lee SS, Sohn WS. Successful management of maternal factor VII deficiency in a cesarean section. Obstetrics & gynecology science. 2014 Jul 15; 57(4): 314-7.
[3]	Hunault, M. and K.A. Bauer. Recombinant factor VIIa for the treatment of congenital factor VII deficiency. in Seminars in thrombosis and hemostasis. 2000. Copyright© 2000 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New ….
[4]	Hasoon, J. and J.M. Rivers, A case of heterozygous factor VII deficiency in pregnancy. Journal of Obstetrics and Gynaecology, 2020. 40(7): p. 1025-1026.
[5]	Jain S, Donkin J, Frey MJ, Peltier S, Gunawardena S, Cooper DL. Phenotypical variability in congenital FVII deficiency follows the ISTH-SSC severity classification guidelines: a review with illustrative examples from the clinic. Journal of Blood Medicine. 2018 Nov 19: 211-8.
[6]	Cramer TJ, Anderson K, Navaz K, Brown JM, Mosnier LO, von Drygalski A. Heterozygous congenital Factor VII deficiency with the 9729del4 mutation, associated with severe spontaneous intracranial bleeding in an adolescent male. Blood Cells, Molecules, and Diseases. 2016 Mar 1; 57: 8-12.
[7]	Alam MM, Moiz B, Rehman KA, Jethwani P, Fadoo Z. Congenital factor VII deficiency in children at tertiary health care facility in Pakistan. Clinical and Applied Thrombosis/Hemostasis. 2015 Oct; 21(7): 639-44.
[8]	Shapiro, A., The use of prophylaxis in the treatment of rare bleeding disorders. Thrombosis Research, 2020. 196: p. 590-602.
[9]	Zaidi, S.M.A., R. Qureshi, and S.N. Adil, Factor VII deficiency and pregnancy: a case report and review of literature. Journal of the Pakistan Medical Association, 2010. 60(2): p. 136.
[10]	Kulkarni, A., C. Lee, and R. Kadir, Pregnancy in women with congenital factor VII deficiency. Haemophilia, 2006. 12(4): p. 413-416.
[11]	Eskandari, N., N. Feldman, and J.S. Greenspoon, Factor VII deficiency in pregnancy treated with recombinant factor VIIa. Obstetrics & Gynecology, 2002. 99(5): p. 935-937.
[12]	Jimenez-Yuste V, Villar A, Morado M, Canales M, Hernandez MC, Sanjurjo MJ, Quintana M, Hernandez-Navarro F. Continuous infusion of recombinant activated factor VII during caesarean section delivery in a patient with congenital factor VII deficiency. Haemophilia: the Official Journal of the World Federation of Hemophilia. 2000 Sep 1; 6(5): 588-90.
[13]	Ariffin H, Millar DS, Cooper DN, Chow T, Lin HP. Prenatal exclusion of severe factor VII deficiency. Journal of pediatric hematology/oncology. 2003 May 1; 25(5): 418-20.
[14]	Loddo A, Cornacchia S, Cane FL, Barcellona D, Marongiu F, Melis GB, Angioni S, Paoletti AM, Neri M. Prophylaxis of peripartum haemorrhage using recombinant factor VIIa (rfVIIa) in pregnant women with congenital factor VII deficiency: A case report and literature review. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2019 Apr 1; 235: 77-80.
[15]	Kolucki FR, Morris GJ, Thomas LC, Scialla S. Factor VII deficiency in pregnancy and delivery: a case report. Haemophilia. 2011 Oct 26; 6(17): e1005-.
[16]	Matei A, Dolan S, Andrews J, Rivard GÉ. Management of labour and delivery in a patient with acquired factor VII deficiency with inhibitor: a case report. Journal of Obstetrics and Gynaecology Canada. 2016 Feb 1; 38(2): 160-3.